APCDD1 and ovarian neoplasm: Overall, the results of this preclinical study suggest that the association of standard drugs with this novel peptidic hTS inhibitor encapsulated into PEGylated pH-sensitive liposomes is a promising strategy to impact the drug resistance problem and, combined with intracellular mechanistic analysis, may represent a rational basis for future clinical applications in ovarian tumor patients.